"No food effects."@en . "For the treatment of adult Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN)."@en . . . "Renal clearance of gabapentin is 5 to 7 L/hr."@en . . "The volume of distribution is 76L."@en . "Gabapentin plasma protein binding is less than 3%."@en . . "XP13512"@en . "Gabapentina enacarbilo"@en . "Horizant"@en . . "Gabapentine enacarbil"@en . . "The elimination half-life of gabapentin is 5.1 to 6.0 hours."@en . . . "Although the exact mechanism of action of gabapentin in RLS and PHN is unknown, it is presumed to involve the descending noradrenergic system, resulting in the activation of spinal alpha2-adrenergic receptors. "@en . . "Gabapentin enacarbil is eliminated primarily in the urine (94%) and to a lesser extent in the feces (5%)."@en . "XP 13512"@en . . "Gabapentin enacarbil is absorbed in the intestines by active transport through the proton-linked monocarboxylate transporter, MCT-1. "@en . "XP-13512"@en . "Most common adverse reactions are headache, dizziness, and somnolence."@en . "478296-72-9"@en . . "gabapentin enacarbil"@en . . . "approved"@en . "Humans and other mammals"@en . "1. Cundy KC, Branch R, Chernov-Rogan T, Dias T, Estrada T, Hold K, Koller K, Liu X, Mann A, Panuwat M, Raillard SP, Upadhyay S, Wu QQ, Xiang JN, Yan H, Zerangue N, Zhou CX, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004 Oct;311(1):315-23. Epub 2004 May 14. "@en . "Gabapentinum enacarbilum"@en . "# Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, Shirsat P, Torneros A, Yao F, Zou J, Barrett RW, Gallop MA: XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004 Oct;311(1):324-33. Epub 2004 May 14. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15146029"@en . "Gabapentin enacarbil is marketed under the name Horizant\u00AE. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN). "@en .